Intellia Therapeutics, Inc.: shareholders and insiders

NTLANASDAQHealthcare · In Vitro & In Vivo Diagnostic Substances

Price

$9.77

November 18, 2026Market cap $1.4B

What Ploutos Investor adds for Intellia Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 3, 2026, from their own Form 4 filings.

14 Form 4s

Bought on the market

$1.4M

1 person

Sold on the market

$2.3M

7 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan58%
  • The rest42%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $1.4M by 1 person·sold $1.4M by 7 people

  • 2025: no buys, sold $836.4K by 1 person
  • 2026: bought $1.4M by 1 person, sold $1.4M by 7 people
  • Nov 2, 2026John M LeonardPresident and CEO
    Kind10b5-1
  • Oct 26, 2026Jing L. MarantzEVP, Chief Medical Officer
    Kind
  • Oct 2, 2026Michael P DubeVP, Chief Accounting Officer
    Kind
  • Aug 21, 2026John M LeonardPresident and CEO
    Kind10b5-1
  • Aug 20, 2026John M LeonardPresident and CEO
    Kind10b5-1
  • Jul 22, 2026Edward J Dulac IIIEVP, Chief Financial Officer
    Kind
  • Jul 2, 2026Edward J Dulac IIIEVP, Chief Financial Officer
    Kind10b5-1
  • Jul 1, 2026Michael P DubeVP, Chief Accounting Officer
    Kind
  • Jun 9, 2026Frank VerwielDirector
    Kind
  • Jun 9, 2026Georgia KerestyDirector
    Kind
  • Jun 9, 2026Jesse GoodmanDirector
    Kind
  • Jun 9, 2026Brian GoffDirector
    Kind
  • Jun 9, 2026Fred E CohenDirector
    Kind
  • Jun 9, 2026William J ChaseDirector
    Kind
  • Jun 9, 2026Muna BhanjiDirector
    Kind
  • Mar 2, 2026Eliana ClarkEVP, Chief Technical Officer
    Kind
  • Mar 2, 2026James BastaEVP, General Counsel
    Kind
  • Jan 5, 2026Fred E Cohen
    Kind
  • Jan 5, 2026Michael P DubeVP, Chief Accounting Officer
    Kind
  • Jan 5, 2026Edward J Dulac IIIEVP, Chief Financial Officer
    Kind
  • Jan 5, 2026Eliana ClarkEVP, Chief Technical Officer
    Kind
  • Jan 5, 2026David LebwohlEVP, Chief Medical Officer
    Kind
  • Jan 5, 2026James BastaEVP, General Counsel
    Kind
  • Jan 5, 2026Birgit C SchultesEVP, Chief Scientific Officer
    Kind
  • Jan 5, 2026John M LeonardPresident and CEO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 10, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by NTLA's officers and directors from 2016 up to November 18, 2025, 10 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

5 Holders over 5%Nov 10, 2026 Latest filing
  • ARK Investment Management LLCwith 1 more person
    Share of class12.3%
  • BlackRock, Inc.
    Share of class8.20%
  • State Street
    Share of class5.60%
  • Vanguard Portfolio Management
    Share of class5.30%
  • Vanguard Capital Management
    Share of class5.03%
Fell to 5% or less (3)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 27, 202613G/A
  • The Goldman Sachs Group2.70%Feb 12, 202613G/A
  • Contrarius Investment Management Ltd0.60%Feb 11, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • D.E. Shaw
    In the quarter-5.9%
  • Bridgewater (Dalio)
    In the quarter
  • Point72 (Cohen)
    In the quarter
  • Renaissance Technologies
    In the quarter-58%
  • Citadel Advisors (Griffin)
    In the quarter-22%
  • Millennium Mgmt (Englander)
    In the quarter-79%
  • AQR Capital
    In the quarter-29%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 31.7% of its shares outstanding were held short, -1.5% since the report before.

Shares held short
44.44M
31.7%
Since the report before45.11M on Sep 30, 2026
-1.5%
6.5
6.89M
More days to cover thanof 4,578 US-listed companies with enough volume
74%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 9.63M
  • Nov 15, 2023: Shares held short 9.47M
  • Nov 30, 2023: Shares held short 9.85M
  • Dec 15, 2023: Shares held short 10.50M
  • Dec 29, 2023: Shares held short 10.16M
  • Jan 12, 2024: Shares held short 10.45M
  • Jan 31, 2024: Shares held short 10.97M
  • Feb 15, 2024: Shares held short 11.63M
  • Feb 29, 2024: Shares held short 12.62M
  • Mar 15, 2024: Shares held short 13.50M
  • Mar 28, 2024: Shares held short 14.83M
  • Apr 15, 2024: Shares held short 14.59M
  • Apr 30, 2024: Shares held short 15.44M
  • May 15, 2024: Shares held short 15.17M
  • May 31, 2024: Shares held short 14.70M
  • Jun 14, 2024: Shares held short 13.74M
  • Jun 28, 2024: Shares held short 13.25M
  • Jul 15, 2024: Shares held short 13.85M
  • Jul 31, 2024: Shares held short 13.37M
  • Aug 15, 2024: Shares held short 13.82M
  • Aug 30, 2024: Shares held short 13.70M
  • Sep 13, 2024: Shares held short 14.76M
  • Sep 30, 2024: Shares held short 15.14M
  • Oct 15, 2024: Shares held short 16.36M
  • Oct 31, 2024: Shares held short 16.15M
  • Nov 15, 2024: Shares held short 16.37M
  • Nov 29, 2024: Shares held short 18.91M
  • Dec 13, 2024: Shares held short 19.81M
  • Dec 31, 2024: Shares held short 21.67M
  • Jan 15, 2025: Shares held short 24.06M
  • Jan 31, 2025: Shares held short 24.06M
  • Feb 14, 2025: Shares held short 24.42M
  • Feb 28, 2025: Shares held short 26.04M
  • Mar 14, 2025: Shares held short 26.69M
  • Mar 31, 2025: Shares held short 26.94M
  • Apr 15, 2025: Shares held short 28.51M
  • Apr 30, 2025: Shares held short 28.75M
  • May 15, 2025: Shares held short 30.70M
  • May 30, 2025: Shares held short 31.56M
  • Jun 13, 2025: Shares held short 29.69M
  • Jun 30, 2025: Shares held short 30.13M
  • Jul 15, 2025: Shares held short 28.87M
  • Jul 31, 2025: Shares held short 29.71M
  • Aug 15, 2025: Shares held short 27.73M
  • Aug 29, 2025: Shares held short 27.74M
  • Sep 15, 2025: Shares held short 34.14M
  • Sep 30, 2025: Shares held short 29.74M
  • Oct 15, 2025: Shares held short 30.90M
  • Oct 31, 2025: Shares held short 39.08M
  • Nov 14, 2025: Shares held short 40.24M
  • Nov 28, 2025: Shares held short 44.57M
  • Dec 15, 2025: Shares held short 40.58M
  • Dec 31, 2025: Shares held short 41.57M
  • Jan 15, 2026: Shares held short 42.56M
  • Jan 30, 2026: Shares held short 45.32M
  • Feb 13, 2026: Shares held short 45.26M
  • Feb 27, 2026: Shares held short 44.31M
  • Mar 13, 2026: Shares held short 39.44M
  • Mar 31, 2026: Shares held short 38.95M
  • Apr 15, 2026: Shares held short 38.81M
  • Apr 30, 2026: Shares held short 43.53M
  • May 15, 2026: Shares held short 51.85M
  • May 29, 2026: Shares held short 48.52M
  • Jun 15, 2026: Shares held short 50.32M
  • Jun 30, 2026: Shares held short 49.22M
  • Jul 15, 2026: Shares held short 45.78M
  • Jul 31, 2026: Shares held short 44.01M
  • Aug 14, 2026: Shares held short 44.88M
  • Aug 31, 2026: Shares held short 43.93M
  • Sep 15, 2026: Shares held short 46.68M
  • Sep 30, 2026: Shares held short 45.11M
  • Oct 15, 2026: Shares held short 44.44M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading53.4% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 53.4% of the shares in the reported trades were short sales, against 44.0% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
53.4%
The 14 beforeOct 12, 2026 – Oct 29, 2026
44.0%
Change
+9.4 pts
Short sales a dayon average, of 1.86M shares
991.4K
More than atof 3,656 US-listed companies, same days
61%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 48.2%
  • Oct 13, 2026: Short sales 50.2%
  • Oct 14, 2026: Short sales 52.3%
  • Oct 15, 2026: Short sales 48.8%
  • Oct 16, 2026: Short sales 41.4%
  • Oct 19, 2026: Short sales 54.1%
  • Oct 20, 2026: Short sales 40.1%
  • Oct 21, 2026: Short sales 46.9%
  • Oct 22, 2026: Short sales 37.5%
  • Oct 23, 2026: Short sales 42.1%
  • Oct 26, 2026: Short sales 49.8%
  • Oct 27, 2026: Short sales 28%
  • Oct 28, 2026: Short sales 37.1%
  • Oct 29, 2026: Short sales 37.3%
  • Oct 30, 2026: Short sales 51.1%
  • Nov 2, 2026: Short sales 52.6%
  • Nov 3, 2026: Short sales 41.8%
  • Nov 4, 2026: Short sales 47.9%
  • Nov 5, 2026: Short sales 55%
  • Nov 6, 2026: Short sales 40.8%
  • Nov 9, 2026: Short sales 45.6%
  • Nov 10, 2026: Short sales 52.6%
  • Nov 11, 2026: Short sales 42.1%
  • Nov 12, 2026: Short sales 53.8%
  • Nov 13, 2026: Short sales 69.8%
  • Nov 16, 2026: Short sales 56.2%
  • Nov 17, 2026: Short sales 57.2%
  • Nov 18, 2026: Short sales 52.4%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

2.80M Insiders' shares2.37% Of the company
  • John M LeonardPresident and CEO
    Directly1.20M
  • Fred E CohenDirector
    Directly216.7K
  • Jing L. MarantzEVP, Chief Medical Officer
    Directly199.8K
  • James BastaEVP, General Counsel
    Directly156.8K
  • Edward J Dulac IIIEVP, Chief Financial Officer
    Directly148.2K
  • William J ChaseDirector
    Directly143.9K
  • David LebwohlEVP, Chief Medical Officer
    Directly121.2K
  • Birgit C SchultesEVP, Chief Scientific Officer
    Directly98.5K
  • Eliana ClarkEVP, Chief Technical Officer
    Directly93.9K
  • Laura Sepp-LorenzinoEVP, Chief Scientific Officer
    Directly77.4K
  • Michael P DubeVP, Chief Accounting Officer
    Directly65.0K
  • Derek HicksEVP, Chief Business Officer
    Directly59.9K
  • Georgia KerestyDirector
    Directly41.1K
  • Glenn GoddardEVP, Chief Financial Officer
    Directly40.6K
  • Muna BhanjiDirector
    Directly36.4K
  • Frank VerwielDirector
    Directly35.1K
  • Jesse GoodmanDirector
    Directly33.6K
  • Brian GoffDirector
    Directly32.6K

A lower bound: it counts only the 18 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

23 ETFs holding it1.92% The largest weight (ARKK)
  • ARKKARK Innovation ETF
    Weight in the fund1.92%
  • ARKGARK Genomic Revolution ETF
    Weight in the fund1.83%
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.91%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.42%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.17%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.15%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.10%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.07%
  • VBKVanguard Small-Cap Growth Index Fund
    Weight in the fund0.06%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.05%

23 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

328 Managers, Q2 2026$2.4B Value of their positions
  • Q3 2025: Managers 285
  • Q4 2025: Managers 293
  • Q1 2026: Managers 306
  • Q2 2026: Managers 328

Institutional investors by quarter

The fund managers holding NTLA, quarter by quarter, from Q1 2016 to Q2 2025, 38 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 328 managers held 144M shares, worth $2.4B. During the quarter 55 opened a position, 33 closed one, 134 added and 81 trimmed.

The largest holders, Q2 2026

  • ARK Investment Management
    In the quarter+16%
  • BlackRock
    In the quarter+27%
  • State Street
    In the quarter+33%
  • Vanguard Portfolio Management
    In the quarter+18%
  • D.E. Shaw
    In the quarter+12%
  • Vanguard Capital Management
    In the quarter+19%
  • Two Sigma Investments
    In the quarter+11%
  • FMR
    In the quarter+131%
  • Ra Capital Management
    In the quarter
  • Regeneron Pharmaceuticals
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Intellia Therapeutics's filings show?

Who buys and sells is one part of Intellia Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NTLA's shareholders

Didn't find what you were looking for?

Ask us
Have NTLA's insiders bought or sold?

From Jun 10, 2026 to Nov 3, 2026 Intellia Therapeutics's insiders bought 0 and sold $637.6K of shares on the market. 75% of the sales were under set 10b5-1 plans.

Which well-known managers hold NTLA?

7 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $73M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.